Chloramphenicol

證據等級: L5

預測適應症: 9 個

Chloramphenicol: From Broad-Spectrum Bacterial Infections to Conjunctivitis

One-Sentence Summary

Chloramphenicol is a classic broad-spectrum antibiotic historically used for serious bacterial infections including typhoid fever, bacterial meningitis, plague, and cholera. The TxGNN model predicts it may be effective for Conjunctivitis, with 0 registered clinical trials but 19 publications — including multiple RCTs — currently supporting this direction. This aligns with chloramphenicol’s longstanding use as a topical ophthalmic antibiotic in the UK, Australia, and many other markets, despite not being registered in India.

Quick Overview

Item	Content
Original Indication	Typhoid fever, bacterial meningitis, serious bacterial infections (not registered in India)
Predicted New Indication	Conjunctivitis
TxGNN Prediction Score	99.66%
Evidence Level	L2
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptidyltransferase activity and preventing peptide chain elongation. This mechanism confers broad-spectrum bacteriostatic activity against the principal pathogens responsible for bacterial conjunctivitis — Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pneumoniae — making the predicted indication pharmacologically coherent.

The key advantage for ophthalmic use lies in its pharmacokinetic profile as a topical formulation. Chloramphenicol eye drops achieve high intraocular concentrations while systemic absorption remains negligible (nanogram/mL range), substantially mitigating the risk of the drug’s most feared adverse effect — aplastic anaemia. The estimated risk of aplastic anaemia from topical ocular use is extremely rare (approximately 1:100,000 to 1:450,000), and this risk-benefit balance has been deemed acceptable in multiple national markets including the UK and Australia, where ophthalmic formulations remain first-line OTC treatments for bacterial conjunctivitis.

The transition from systemic bacterial infections to a topical ophthalmic indication therefore represents not so much a novel repurposing as a route-of-administration extension with decades of real-world precedent. The TxGNN model’s high confidence score (99.66%) is reinforced by a substantial body of published RCTs and systematic reviews comparing chloramphenicol eye drops against alternative topical antibiotics.

Clinical Trial Evidence

No registered clinical trials specifically evaluating Chloramphenicol for conjunctivitis were identified in ClinicalTrials.gov or ICTRP at the time of data collection.

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32959365	2020	Cochrane Systematic Review	The Cochrane Database of Systematic Reviews	Interventions for preventing ophthalmia neonatorum; evaluates chloramphenicol among antiseptic/antibiotic agents to prevent neonatal conjunctivitis and potential vision impairment
16378567	2005	Systematic Review	Br J Gen Pract	Updated meta-analysis of topical antibiotics (including chloramphenicol) vs placebo for acute bacterial conjunctivitis in primary care; supports benefit of topical antibiotic therapy
3554881	1987	RCT	Acta Ophthalmologica	Single-blind RCT (n=250); chloramphenicol 0.5% vs fusidic acid 1% — clinical success 81% vs 84%; chloramphenicol had slightly higher rate of mild local side effects (14% vs 5%)
8333258	1993	RCT	Acta Ophthalmologica	RCT (n=38 GPs in Norway); fusidic acid twice daily vs chloramphenicol 6×/day in acute conjunctivitis — no significant difference in bacteriological findings or treatment response
3300139	1987	RCT	Acta Ophthalmologica	Open RCT in Tanzania; fusidic acid superior to chloramphenicol eye drops (93% vs 48% clinical success); chloramphenicol showed high in vitro resistance rate in study population
17947266	2007	RCT	Br J Ophthalmology	Randomised equivalency trial (trachoma-endemic area, Mexico); 2.5% povidone-iodine vs ophthalmic chloramphenicol for preventing neonatal conjunctivitis
38511104	2024	Comparative Study	Curr Ther Res	Head-to-head comparison of moxifloxacin vs chloramphenicol for bacterial eye infections; contextualises chloramphenicol’s bacteriostatic mechanism and known toxicity profile in modern ophthalmic practice
8800624	1996	Review	Drug Safety	Critical review of the evidence for and against an association between topical ocular chloramphenicol and aplastic anaemia; widely used in UK for conjunctivitis despite controversy
6188739	1983	RCT (multicentre)	J Antimicrob Chemother	n=230; trimethoprim-polymyxin B vs chloramphenicol ophthalmic solution in bacterial conjunctivitis — all preparations shown effective with few adverse events
23571246	2014	Observational	Indian J Ophthalmology	Profiles non-chlamydia conjunctival bacteria and antimicrobial susceptibility in rural Ethiopia after trichiasis surgery; includes chloramphenicol resistance data

India Market Information

Chloramphenicol has no registered products in India at the time of data collection (0 licences, market status: Not Marketed).

No products currently registered in India. Ophthalmic formulations are marketed in the UK (prescription-exempt), Australia, and other countries.

Safety Considerations

Drug Interactions (478 interactions documented; clinically significant interactions listed below):

Severity	Interacting Drug(s)	Clinical Concern
Major	Cisapride	Potential for cardiac arrhythmia; co-administration contraindicated
Major	Naloxegol	CYP3A4 inhibition by chloramphenicol may markedly increase naloxegol exposure
Moderate	Acetohexamide, Chlorpropamide, Glimepiride, Glipizide, Glyburide, Repaglinide	CYP2C9 inhibition may prolong/enhance hypoglycaemic effect of sulphonylureas and repaglinide; blood glucose monitoring recommended
Moderate	Saxagliptin	Increased saxagliptin exposure via CYP3A4/CYP2C8 inhibition
Moderate	Simvastatin, Rosuvastatin	Increased statin plasma levels; risk of myopathy/rhabdomyolysis
Moderate	Budesonide, Budesonide (nasal)	Inhibition of corticosteroid metabolism; increased systemic steroid exposure
Moderate	Metronidazole	Pharmacodynamic/pharmacokinetic interaction; enhanced CNS adverse effects possible
Moderate	Iron	Chloramphenicol may delay erythropoietic response to iron supplementation
Moderate	Aprepitant, Eliglustat, Naldemedine, Nitisinone, Balsalazide	Variable mechanisms; clinical monitoring advised

Note: Warnings and contraindications data were not available in this Evidence Pack. Please refer to the official package insert and current prescribing information for complete safety details.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple published RCTs and a Cochrane systematic review establish chloramphenicol ophthalmic solution as an effective treatment for bacterial conjunctivitis, and the drug holds regulatory approval for this indication in the UK and Australia. The TxGNN prediction is well-supported by biological plausibility and real-world evidence, representing a route-of-administration adaptation rather than a novel mechanistic repurposing. The primary risk — aplastic anaemia — is quantifiable and extremely rare with topical ocular use, which is standard practice globally.

To proceed, the following is needed:

Regulatory filing strategy: Chloramphenicol ophthalmic drops are not registered in India; a new drug/licence application for ophthalmic formulation would be required
Full safety data package: Retrieve CDSCO-equivalent warnings, contraindications, and the official DrugBank MOA entry to complete the safety profile (DG001, DG002 currently blocking)
Resistance surveillance data for India: Resistance rates observed in the 1987 Tanzania RCT (48% clinical success) highlight geographic variability — local S. aureus, H. influenzae, and S. pneumoniae susceptibility data from India should be reviewed before launch
Aplastic anaemia risk communication plan: A clear patient and prescriber communication strategy is required given the historical safety debate, even though topical risk is extremely low
Comparator positioning: Define competitive positioning against moxifloxacin, tobramycin, and other topical antibiotics available in the Indian market
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.